AZN Stock Recent News

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasthenia gravis in adults.

Bloomberg's 50 Companies to Watch leverages catalysts like new leadership, AI, and policy shifts to identify high-potential stocks for 2025. Yield-based 'dogcatcher' analysis spotlights 15 dividend payers with strong free cash flow, with five 'IDEAL' stocks signaling safer, buy-worthy dividends. Top ten dividend focus stocks project an average 16.69% net gain by July 2026, with risk profiles generally below market averages.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.

AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.

AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant's largest-ever investment in a single market. The UK-headquartered biopharmaceutical company said the investment will expand its domestic manufacturing and research footprint as it works toward a long-term revenue target of $80 billion annually, with half of that total expected to come from the US market.

Stock futures are little changed as investors watch for more earnings and trade developments; AstraZeneca (AZN) said it plans to invest $50 billion in U.S. production facilities; Opendoor Technologies (OPEN) shares are on the rise as retail investors continue to pile into the meme stock; and OpenAI and Softbank are reportedly paring back near-term plans for their $500 billion Stargate project. Here's what investors need to know today.

AstraZeneca (AZN) said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about President Donald Trump's tariffs loom over the industry.

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it's already announced before.